Literature DB >> 23158059

Chromosome damage and cell proliferation rates in in vitro irradiated whole blood as markers of late radiation toxicity after radiation therapy to the prostate.

Lindsay A Beaton1, Catherine Ferrarotto, Leonora Marro, Sara Samiee, Shawn Malone, Scott Grimes, Kyle Malone, Ruth C Wilkins.   

Abstract

PURPOSE: In vitro irradiated blood samples from prostate cancer patients showing late normal tissue damage were examined for lymphocyte response by measuring chromosomal aberrations and proliferation rate. METHODS AND MATERIALS: Patients were selected from a randomized trial evaluating the optimal timing of dose-escalated radiation and short-course androgen deprivation therapy. Of 438 patients, 3% experienced grade 3 late radiation proctitis and were considered to be radiosensitive. Blood samples were taken from 10 of these patients along with 20 matched samples from patients with grade 0 proctitis. The samples were irradiated at 6 Gy and, along with control samples, were analyzed for dicentric chromosomes and excess fragments per cell. Cells in first and second metaphase were also enumerated to determine the lymphocyte proliferation rate.
RESULTS: At 6 Gy, there were statistically significant differences between the radiosensitive and control cohorts for 3 endpoints: the mean number of dicentric chromosomes per cell (3.26 ± 0.31, 2.91 ± 0.32; P=.0258), the mean number of excess fragments per cell (2.27 ± 0.23, 1.43 ± 0.37; P<.0001), and the proportion of cells in second metaphase (0.27 ± 0.10, 0.46 ± 0.09; P=.0007).
CONCLUSIONS: These results may be a valuable indicator for identifying radiosensitive patients and for tailoring radiation therapy. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23158059     DOI: 10.1016/j.ijrobp.2012.09.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Flow cytometry-assisted quantification of γH2AX expression has potential as a rapid high-throughput biodosimetry tool.

Authors:  Daniel G Achel; Antonio M Serafin; John M Akudugu
Journal:  Radiat Environ Biophys       Date:  2016-06-04       Impact factor: 1.925

2.  DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.

Authors:  Melvin Lee Kiang Chua; Simon Horn; Navita Somaiah; Sue Davies; Lone Gothard; Roger A'Hern; John Yarnold; Kai Rothkamm
Journal:  Radiat Environ Biophys       Date:  2014-03-13       Impact factor: 1.925

3.  Investigation of Chromosome 1 Aberrations in the Lymphocytes of Prostate Cancer and Benign Prostatic Hyperplasia Patients by Fluorescence in situ Hybridization.

Authors:  Justyna Miszczyk; Mikołaj Przydacz; Michał Zembrzuski; Piotr L Chłosta
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

Review 4.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

5.  Differences in DNA Repair Capacity, Cell Death and Transcriptional Response after Irradiation between a Radiosensitive and a Radioresistant Cell Line.

Authors:  Mireia Borràs-Fresneda; Joan-Francesc Barquinero; Maria Gomolka; Sabine Hornhardt; Ute Rössler; Gemma Armengol; Leonardo Barrios
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

6.  Investigating γ H2AX as a Biomarker of Radiosensitivity Using Flow Cytometry Methods.

Authors:  Lindsay A Beaton; Leonora Marro; Shawn Malone; Sara Samiee; Scott Grimes; Kyle Malone; Ruth C Wilkins
Journal:  ISRN Radiol       Date:  2013-04-10

Review 7.  Clinical and Functional Assays of Radiosensitivity and Radiation-Induced Second Cancer.

Authors:  Mohammad Habash; Luis C Bohorquez; Elizabeth Kyriakou; Tomas Kron; Olga A Martin; Benjamin J Blyth
Journal:  Cancers (Basel)       Date:  2017-10-27       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.